Back
Beam Therapeutics 10K Form
Sell
18
BEAM
Beam Therapeutics
Last Price:
$15.48
Seasonality Move:
20.64%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-08 | 10Q | BEAM/Beam Therapeutics Quarterly |
| 2023-08-08 | 10Q | BEAM/Beam Therapeutics Quarterly |
| 2023-05-10 | 10Q | BEAM/Beam Therapeutics Quarterly |
| 2022-11-07 | 10Q | BEAM/Beam Therapeutics Quarterly |
| 2022-08-09 | 10Q | BEAM/Beam Therapeutics Quarterly |
| 2022-05-09 | 10Q | BEAM/Beam Therapeutics Quarterly |
Receive BEAM News And Ratings
See the #1 stock for the next 7 days that we like better than BEAM
BEAM Financial Statistics
Sales & Book Value
| Annual Sales: | $63.5M |
|---|---|
| Cash Flow: | $-79.3M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $8.77 |
| Price / Book: | 1.76 |
Profitability
| EPS (TTM): | -4.58000 |
|---|---|
| Net Income (TTM): | $-376.7M |
| Gross Margin: | $1.5B |
| Return on Equity: | -44.08% |
| Return on Assets: | -29.64% |
Beam Therapeutics Earnings Forecast
Key Beam Therapeutics Financial Ratios
-
The Gross Profit Margin over the past 10 years for BEAM is 58.08%.
-
The Selling, General & Administrative Expenses for BEAM have been equal to 175.58% of Gross Profit Margin.
-
The Research & Development expenses have been 578.67% of Revenue.
-
The Net Earning history of BEAM is -593.13% of Total Revenues.
-
Per Share Earnings over the last 17 years have been positive in 6 years.
Beam Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | BEAM |
| CUSIP: | 07373V |
| Website: | beamtx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 4.82 |
| Quick Ratio: | 4.67 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
BEAM Technical Analysis vs Fundamental Analysis
Sell
18
Beam Therapeutics (BEAM)
is a Sell
Is Beam Therapeutics a Buy or a Sell?
-
Beam Therapeutics stock is rated a SellThe current Beam Therapeutics [BEAM] share price is $15.47. The Score for BEAM is 18, which is 64% below its historic median score of 50, and infers higher risk than normal.